BidaskClub Lowers Kalvista Pharmaceuticals (KALV) to Hold

BidaskClub cut shares of Kalvista Pharmaceuticals (NASDAQ:KALV) from a buy rating to a hold rating in a research note published on Thursday morning.

Other research analysts have also issued research reports about the company. Cantor Fitzgerald set a $32.00 price objective on Kalvista Pharmaceuticals and gave the company a buy rating in a research report on Wednesday, October 3rd. Zacks Investment Research lowered Kalvista Pharmaceuticals from a buy rating to a sell rating in a research report on Thursday, September 20th. Jefferies Financial Group assumed coverage on Kalvista Pharmaceuticals in a research report on Tuesday, October 30th. They set a buy rating and a $30.00 price objective for the company. TheStreet upgraded Kalvista Pharmaceuticals from a d+ rating to a c- rating in a research report on Thursday, December 20th. Finally, Stifel Nicolaus assumed coverage on Kalvista Pharmaceuticals in a research report on Monday, October 15th. They set a buy rating for the company. One analyst has rated the stock with a hold rating and seven have assigned a buy rating to the company. The company presently has an average rating of Buy and an average target price of $26.00.

Shares of Kalvista Pharmaceuticals stock traded down $1.44 during trading on Thursday, reaching $16.71. 110,208 shares of the stock traded hands, compared to its average volume of 48,864. Kalvista Pharmaceuticals has a 52-week low of $7.73 and a 52-week high of $25.57.

Kalvista Pharmaceuticals (NASDAQ:KALV) last issued its quarterly earnings data on Friday, December 14th. The specialty pharmaceutical company reported ($0.22) earnings per share for the quarter, beating the Zacks’ consensus estimate of ($0.46) by $0.24. The firm had revenue of $5.59 million during the quarter, compared to analyst estimates of $3.70 million. Kalvista Pharmaceuticals had a negative return on equity of 29.46% and a negative net margin of 84.47%. Analysts anticipate that Kalvista Pharmaceuticals will post -1.82 earnings per share for the current fiscal year.

In related news, CEO Thomas Andrew Crockett sold 10,000 shares of Kalvista Pharmaceuticals stock in a transaction dated Monday, January 14th. The stock was sold at an average price of $19.33, for a total value of $193,300.00. Following the completion of the transaction, the chief executive officer now owns 272,411 shares in the company, valued at $5,265,704.63. The transaction was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, major shareholder Svlsf Iv, Llc sold 25,418 shares of Kalvista Pharmaceuticals stock in a transaction dated Tuesday, December 31st. The stock was sold at an average price of $20.00, for a total value of $508,360.00. The disclosure for this sale can be found here. In the last quarter, insiders sold 49,787 shares of company stock valued at $988,469. 38.40% of the stock is currently owned by company insiders.

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Virtu Financial LLC purchased a new position in Kalvista Pharmaceuticals in the third quarter worth about $216,000. Dimensional Fund Advisors LP purchased a new position in Kalvista Pharmaceuticals in the third quarter worth about $274,000. BlackRock Inc. grew its position in Kalvista Pharmaceuticals by 203.8% in the second quarter. BlackRock Inc. now owns 16,205 shares of the specialty pharmaceutical company’s stock worth $132,000 after acquiring an additional 10,871 shares in the last quarter. Wells Fargo & Company MN purchased a new position in Kalvista Pharmaceuticals in the third quarter worth about $598,000. Finally, EAM Investors LLC purchased a new position in Kalvista Pharmaceuticals in the third quarter worth about $926,000. Institutional investors own 72.95% of the company’s stock.

About Kalvista Pharmaceuticals

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Further Reading: Outstanding Shares, Buying and Selling Stocks

Analyst Recommendations for Kalvista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply